BI 60732Alternative Names: BI60732
Latest Information Update: 04 Oct 2014
At a glance
- Originator Boehringer Ingelheim
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 30 Jun 2010 Discontinued - Phase-I for Thrombosis (In volunteers) in Germany (PO)